Abstract. A method of 11 C-methionine synthesis using 'bubbling' method is presented.
Introduction
Positron emission tomography (PET) is dynamically developing imaging method of nuclear medicine, which allows to diagnose metabolic changes in the human body. Among the  + emitting isotopes, produced in medical cyclotrons, carbon-11 is the most convenient radionuclide for labeling of biologically active compounds and tracking their distribution in living organism. Although 18 F with t 1/2 = 109.8 min is routinely applied as a tracer in commercially available radiopharmaceuticals for neuro-and oncological diagnostics, 11 C (t 1/2 = 20.4 min) is often chosen for radiolabeling of the endogenous or investigative compounds -neurotransmitters, amino acids, drugs and drug candidates. Replacement of carbon-12 with carbon-11 does not alter the biochemical properties of a molecule. So a labeled compound is incorporated in metabolic processes and follows the same path as its natural equivalent. Moreover, using the position-specifi c methylation approach, imaging of metabolites, and metabolic paths of selected functional groups expands the biological information on molecular level. 11 C-methionine increased its clinical signifi cance when the methionine uptake was identifi ed as one of the critical factors in tumor growth [1, 2] and started to be a standard method for visualization of gliomas in neurooncology [3] [4] [5] as well as a supplementary in adenocarcinoma [6] or radiation therapy planning [7] . This paper describes a simple and low-cost method for routine production of 11 C-methionine. The scope of this study was to synthesize 11 C-methionine in a number of consecutive runs and to prove the quality of manufactured radiopharmaceuticals, as a preliminary step in human applications and animal studies.
Materials and methods

11
C production 11 CO 2 was produced by the 14 N(p,) 11 C reaction with 16.5 MeV proton beam at 20-25 A in GE Pettrace 840 cyclotron (General Electric, Uppsala, Sweden). The target was gaseous N 2 (6.0), containing 5% O 2 (5.5) in high pressure (170 psi) target body (GE, Uppsala, Sweden).
11 C was produced with a total activity of ca. 1000 mCi (37 GBq) after 10-15 min irradiation with 25-30 A beam current. Then gaseous products were transferred via stainless steel tubing to synthesizer Synthra MeI Plus (Synthra, Germany) ( Fig. 1) , located in MIP-1100 hotcell (Comecer, Italy), 75 mm shielded, with air compressing system (ACS), collecting radioactive gaseous exhausts from all reaction steps to shield the pressure tanks.
C-methionine synthesis 11 C-methionine was synthesized via 11 C methylation from L-cysteine thiolactone (ABX, Radeberg, Germany) in solution using the 'bubbling' method [8] . Target gases were passed through cryogenic trap, where 11 CO 2 was deposited at -165C. Then 11 CO 2 was converted to methane (H 2 /Ni, 400°C) and 11 C-methyliodide was synthesized by passing the 11 C-CH 4 over iodine in a triplicate loop at an elevated temperature (720°C) and trapping on a Porapak column (dry method). Thermally desorbed 11 CH 3 I was bubbled into the reactor with L-homocysteine thiolactone (2 mg) in a 300 L solution of 2:1:1 (v/v) 1 M NaOH, ethanol, and water at ambient temperature (85°C, 5 min). The product was then purifi ed by semipreparative HPLC (C18 column, 0.05 M NaH 2 PO 4 + 2% EtOH as mobile phase) with a total wet-synthesis time of 20 min (Fig. 2) .
The fi nal product was formulated with phosphate buffer, passed through a 0.22 m fi lter and dispensed in automatic module DDS-Vials (Tema-Synergie, Italy).
Identifi cation and quality control
Identifi cation tests were performed as described in [9] . For -spectrometry, high-resolution germanium detector GMX-20190-P with digital signal processor (DSPEC, Ortec) and GammaVison software was used. A 2 L of sample was applied on silica plate, fi xed in a holder, and inserted into a 5 cm Pb shielded, low-background housing. Spectra was recorded for 5 min immediately after synthesis.
Half-life was measured with Atomlab300 (Biodex, USA) dose calibrator: 300 L (0.6-0.8 GBq) sample was crimped in a penicillin vial, fi xed in a standard vial holder and measured in triplicate at 5 min intervals.
The identity of the manufactured 11 C-methionine was confi rmed by comparison of retention time to the certifi ed reference standard (CRS) of the main compound (ABX, Radeberg, Germany).
Radiochemical purity test A was performed with an ion chromatography system Shimadzu AD-20 with a diode array and radiometric (Gabi-Star, Raytest) detectors.
A 10 L sample was injected via a manual multiport valve. The separation was done on Phenomenex Gemini C18 250 mm × 4.6 mm × 5 m column with 1.4 g/L solution of potassium dihydrogen phosphate as a mobile phase and 1 mL/min fl ow rate. Data acquisition and processing were performed with LCsolution ® software. Enantiomeric purity was determined by chiral HPLC, using a Shimadzu AD-20 equipped with a diode array and radiometric detector. A Chirobiotic T column with teicoplanine as chiral selector (150 mm × 4.6 mm × 5 m, Astec) was used as a stationary phase with acetonitrile : water 70 : 30 mobile phase at a fl ow rate 1 ml/min [10] .
Measurements of pH were conducted with MulitiSeven pH-meter (Mettler-Toledo, Germany) with microelectrode vs. 4.01, 7.01, and 9.21 buffers (Hamilton, UK).
Head-space gas chromatography was performed on 7890A Agilent system, equipped with a J&W HP-5 column (30 m × 0.32 mm × 0.25 m) and a fl ame ionization detector (FID). GC system was supplied with an H 2 (30 mL/min) from CFH200 generator (Peak Scientifi c, UK), ensuring 99.9995% B of hydrogen purity, zero-air (400 mL/min) from a Jun-Air 0F301-4B generator (Jun-Air, UK), and He (6.0, Air Products, fl ow rate 25 mL/min). Gas chromatographic system was operated on the following conditions: oven temperature 40°C for 1 min, inlet temperature 150°C, detector temperature 180°C. The samples were injected via 7694E Agilent head--space system. For a comfortable sample application, 5-L single-use capillaries (Drummond Scientifi c, USA) were used for transfer of the radioactive sample to 10 mL penicillin vials with aluminum caps and PTFE/Si septa (Agilent). Head-space injector was set to 80°C for 2 min, and then the sample was equilibrated for 0.2 min and transferred to the GC system. The loop and transfer line were heated to 105°C and 110°C, respectively. Chemstation software was used for operation of chromatograph, acquisition, and processing of data.
To ensure the quality of measurements, methods were developed and validated with certifi ed reference standards (CRS) of main compound and impurities.
Results and discussion
Synthesis 11 C-methionine was synthesized by conventional 'bubbling' method [8] .
11
CH 3 I was passed through the reactor, containing precursor, L-homocysteine thiolactone in the presence of ethanol and sodium hydroxide. The reaction was followed with preparative HPLC, ensuring good separation of fi nal product from impurities. Radiochemical yield was 21.3 ± 4.6% (not corrected), total synthesis time, including activity transfer, gas phase iodination of CH 4 , labeling, purifi cation, and fi nal formulation was 27-32 min. The produced activity was suffi cient for the injection of two patients in a standard imaging mode. Recently, synthesis on solid supports has gained some more attention due to simplicity (room temperature, immobilized precursor) and shorter reaction time (elimination of time-consuming preparative HPLC purifi cation). The described methods using on-column precursor deposition [11, 12] or on-loop synthesis [13] showed excellent potential (radiochemical yield >60%, reaction time 11-13 min, radiochemical purity >99%) but relatively short half--life still limited application to two to three patients from a single run.
Identifi cation
11 C was identifi ed by recording the principal -peak at 511.5 ± 0.3 keV (Fig. 3) and determination of half-life (20.5 ± 0.3 min).
11
C-methionine was confi rmed, comparing the retention times of standards, observed in the reference chromatogram with retention time of the principal signal in the radiochromatogram (Fig. 4) . Recorded retention times were 3.05 min for the standard and 3.07 min for the principal peak in radiochromatogram. 
Radionuclidic purity
Gamma spectrum recorded for identifi cation was used for the determination of radionuclidic purity. The presence of any peaks with an energy different from 511 keV was checked and, except signals coming from Pb-X-rays (range 70-80 keV), none was found. That confi rmed a better than 99.9% radionuclidic purity. Then 11 C-methionine sample was left for 2 h to decay the carbon and again impurities were tested with no signifi cant peaks, except residual activity of 11 C. The abovementioned results complied with radionuclidic purity tests A and B.
Purity
Chemical purity was determined in all produced 11 C-methionine samples. L-homocysteine thiolactone hydrochloride (impurity A), 11 C-methionine, and homocysteine (impurity B) were identifi ed by a qualitative comparison with the reference solution, containing maximum available concentration of respective CRS as described in [9] . The retention times were 2.51 min for impurity B, 3.05 min for methionine, and 3.72 min for impurity A, which corresponded to resolution factors 1.02 and 1.28 vs. metionine. In all 11 C-methionie samples, the area of the corresponding peaks were smaller than obtained with reference solution and signal from precursor (L-homocysteine thiolactone hydrochloride) was negligible or not even observed (Fig. 4) .
Radiochemical purity was determined by high--performance liquid chromatography (HPLC) with radiometric detection, where the peak of 11 C-methionine was observed at 3.07 min, with no other signals recorded (Fig. 5) . The average content of 11 C-methionine was higher than 99%. Six consecutive runs were analyzed in triplicate each.
The synthesis on solid support with SPE separation showed the presence of precursor in the fi nal formulation [14, 15] , lower radiochemical purity (98% [15] , 97-99% [14] ) and additional impurities (iodide, homocystine [16] ) but still at the acceptable level. It could be explained with more effi cient preparative HPLC purifi cation than SPE, resulting in the separation of reaction mixture to its individual components and controlled collection of 11 C-methionine fraction.
Enantiomeric purity was assessed by chiral HPLC. L-and D-isomers were identifi ed by HPLC with UV and radiometric detectors (Fig. 6) . The percentage of L-11 C-methionine was 91.6 ± 0.4%. Other recently published papers reported values from 89% [14] to pure L-isomer [13] . The commonly used method for enantiomers determination is chiral HPLC, instead of the time-consuming pharmacopoeial TLC method. Two approaches are applied: fi rst with chiral column [13] and the other with C8-18 reverse phase chromatography with L-proline in mobile phase as a chiral selector [14, 17] . Nevertheless, the D-form does not infl uence tumor uptake [18] .
Residual organic solvents
The analysis of methionine samples needs to consider a certain percentage of ethanol.
11 C-methione is autodegraded by its own radiation [19] and an important issue is to ensure the stability in routine production due to radiolysis. Thus up to several percent of ethanol may be added as a scavenger and a stabilizer [20] . The produced 11 C-methionine formulations were tested and the mean value of the ethanol concentration was 33 ± 2 g/L. No traces of C -methionine. Acceptance criteria according to [9] . Other tests pH, sterility, and endotoxin test, as generally known procedures, are summarized in Table 1 . All parameters were according to the quality criteria for 11 C-methionine.
Conclusions
In this work, the 'bubbling' method of 11 C-metionine synthesis as an alternative way to SPE synthesis was presented. The fi nal product met the requirements of European Pharmacopoeia monograph. All the impurities were effi ciently determined and then eliminated in the purifi cation process. The fi nal product was free from main radionuclidic and chemical impurities. The proposed 11 C-methionine synthesis is a reliable tool for routine manufacturing in clinical applications and animal studies.
